River Head Capital is the private equity arm of the Sunshine Insurance Group.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
River Head Capital is the private equity arm of the Sunshine Insurance Group. River Head Capital was established in January 2015. It is the first batch of insurance private fund pilot units approved by the China Insurance Regulatory Commission. The fund management scale has reached 17 billion yuan. Adhering to the corporate vision of “making life better”, with the mission of “creating value, trustworthiness, investing resources in the most valuable companies, and gaining the trust of investors with excellent returns”, the company will actively deploy medical health and emerging Industries, emerging consumption, industrial mergers and acquisitions, real estate and other fields, through entrepreneurial support, strategic investment, financial investment, mergers and acquisitions, corporate restructuring, cross-border investment and other diversified ways to invest in enterprises, comprehensively enhance corporate value and support the healthy and sustainable development of enterprises. At present, River Head Capital has invested in a number of companies in the fields of medical, pharmaceutical, Internet, and innovative financial services.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2017 | Meilianzhonghe Veterinary Hospital | Series A | 1.5M |
4/2016 | Miao | Series A | 15.4M |
8/2020 | Ruipeng Pet Healthcare | Venture Round | - |
10/2015 | Mass Medical International | Angel Round | 471.9k |
1/2020 | Sunny Dental | Series A | 28.7M |
7/2020 | AW Education International | Series B | 28M |
5/2019 | RUNDO | Series C | 15M |
6/2019 | Enflame | Series A | 0 |
6/2020 | Eswin | Series B | 282.6M |
12/2015 | You Liang Sheng Huo | Angel Round | 468.8k |
1/2023 | Huzhou Shenke | Series B | - |
6/2019 | Chao Ju Ophthalmology | Series C | - |
7/2018 | Lionbridge Financing Leasing | Corporate Round | 149.1M |
8/2020 | Lepu Bio | Series B | 185.7M |
6/2017 | QingCloud | Series D | 0 |
10/2020 | Sirnaomics | Series D | 0 |
9/2022 | Cell Probio | Series B | - |
1/2016 | Yingyuqu Peiyin | Seed Round | 455.6k |
5/2023 | Bio-Engine | Series C | 0 |
1/2023 | Sijie Microelectronics | Series C | - |
11/2017 | Ruipeng Pet Healthcare | Corporate Round | 37M |
2/2016 | Yangguang Huxin | Angel Round | 38.3k |
9/2022 | WuXi Bo Rui | Series A | 42M |
10/2020 | Sirnaomics | Series D | 0 |
8/2020 | Lepu Bio | Series B | 0 |
8/2020 | Ruipeng Pet Healthcare | Venture Round | - |
7/2020 | AW Education International | Series B | 0 |
6/2020 | Eswin | Series B | 0 |
1/2020 | Sunny Dental | Series A | 0 |
6/2019 | Chao Ju Ophthalmology | Series C | - |
6/2019 | Enflame | Series A | 0 |
5/2019 | RUNDO | Series C | 0 |
7/2018 | Lionbridge Financing Leasing | Corporate Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|